数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
In particular, it remains important to distinguish whether associations between relative CSF–plasma signals and AD clinical stage reflect changes in CSF, plasma, or their differing disease-related patterns.
方法
Participants were included when matched CSF and plasma samples were collected within 30 days and clinical diagnostic information was available.；The final paired cohort comprised 1199 participants (CN, n = 436; MCI, n = 568; AD dementia, n = 195) and 125 matched analyte readouts.
核心结论
APOE ε4 carrier frequency increased across the clinical groups, from 30.7% in CN to 50.0% in MCI and 71.3% in AD dementia (p < 0.001).；Cognitive and functional measures followed the expected clinical gradient: the mean MMSE decreased from 29.1 in CN to 27.7 in MCI and 23.2 in AD dementia, while the median CDR-SB increased from 0.0 to 1.5 and 4.5 (both p < 0.001).；CSF Aβ42/40-derived amyloid burden increased across CN, MCI, and AD dementia, and CSF pTau217 increased in parallel (both p < 0.001). ‖ 结论：These findings extend previous paired-proteomic observations of protein-specific CSF–plasma relationships in aging and cognitive impairment [22] by characterizing their associations with AD clinical stage and examining the subsequent clinical relevance of selected analyte patterns.
局限
The biological composition of the stage-associated pattern suggests that analyte-specific cross-biofluid heterogeneity extends beyond canonical amyloid and tau biomarkers.；The longitudinal analysis further linked these cross-biofluid patterns to clinical heterogeneity within MCI.；First, this study was conducted exclusively within ADNI, which may limit the generalizability of our findings to more heterogeneous clinical populations.
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。队列：ADNI、GTEx；最大样本量约 1,199；设计 前瞻队列、横断面。
全文来源
PMC JATS 全文（正文 29,128 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Paired CSF-Plasma Analyte Signal Contrasts Across Alzheimer's Disease Clinical Stages and MCI-to-Dementia Conversion.
- 期刊与标识：Biomedicines · PMID 42940213 · DOI 10.3390/biomedicines14102407**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。